Jefferies downgraded Horizon Therapeutics (HZNP) to Hold from Buy after Amgen (AMGN) and Horizon announced the entry into a consent order agreement that resolves the pending FTC administrative lawsuit and “clears the path to take the final steps to close Amgen’s acquisition of Horizon.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HZNP:
- Horizon Therapeutics (NASDAQ:HZNP) Gains after FTC Settlement
- Amgen, Horizon enter consent order agreement with FTC to close acquisition
- AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION
- Amgen, Horizon Therapeutics confirm resolution of FTC lawsuit
- Amgen to settle FTC and state challenges to Horizon Therapeutics takeover